End-organ dysfunction in cystic fibrosis: Association with angiotensin I converting enzyme and cytokine gene polymorphisms

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 3, 2003, Pages 384-389

  Arkwright, Peter D ^a   Pravica, Vera ^b   Geraghty, Philip J ^b   Super, Maurice ^b   Webb, A Kevin ^b   Schwarz, Martin ^b   Hutchinson, Ian V ^b  

^a BOOTH HALL CHILDREN S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Angiotensin I converting enzyme; Cirrhosis; Cystic fibrosis; Lung; Transforming growth factor 1

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; ECHOGRAPHY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 0037323317     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200204-364OC     Document Type: Article

References (39)

1. Burke W, Aitken ML, Chen SH, Scott CR. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. Chest 1992;102:506-509.
2. Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-1313.
3. Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, Strandvik B, McKenzie SG. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiology Registry of Cystic Fibrosis. Eur Respir J 2001;18:298-305.
4. Schechter MS, Shelton B, Margolis PA, Fitzsimmons SC. The association of socio-economic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-1337.
5. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
6. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-2118.
7. Poschet JF, Boucher JC, Tatterson L, Skidmore J, Van Dyke RW, Deretic V. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc Natl Acad Sci USA 2001;98:13972-13977.
8. 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-1020.
9. 1 and tumour necrosis factor-α: a technical report. Transpl Immunol 1998;6:193-197.
10. 1 gene polymorphisms. Transpl Immunol 1999;7:127-128.
11. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur J Immunogenet 1999;26:1-3.
12. Nguyen L, Ward WF, Ts'ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994;205:80-84.
13. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997;17:467-491.
14. Peters H, Border WA, Noble NA. Targeting TGF-β overexpression in renal disease: maximizing the anti-fibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570-1580.
15. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992;18:29-43.
16. Corrin B, Butcher D, McAnulty BJ, Dubois RM, Black CM, Laurent GJ, Harrison NK. Immunohistochemical localization of transforming growth factor-β in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-150.
17. Franko AJ, Sharplin J, Ghahary A, Barcellos-Hoff MH. Immunochemical localization of transforming growth factor β and tumour necrosis factor α in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res 1997;147:245-256.
18. El-Gamel A, Sim E, Haseleton P, Hutchinson J, Yonan N, Egan J, Campbell C, Rahman A, Sheldon S, Deiraniya A, et al. Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999;18:828-837.
19. 1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrinogenesis. Am J Physiol 1999;276:G1059-G1068.
20. 1 overexpression in tumor necrosis factor-α receptor knockout mice induces fibroproliferative lung disease. Am J Respir Cell Mol Biol 2001;25:3-7.
21. 1 genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000;55:459-462.
22. De Assis MC, Costa AO, Barja-Fidalgo TC, Plotkowski MC. Human endothelial cells are activated by interferon-γ plus tumour necrosis factor-α to kill intracellular Pseudomonas aeruginosa. Immunology 2000;101:271-278.
23. Yu H, Nasr SZ, Deretic V. Innate lung defences and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis. Infect Immun 2000;68:2142-2147.
24. Welsh MJ, Smith AE. Molecular mechanisms of CFTR dysfunction in cystic fibrosis. Cell 1993;73:1251-1254.
25. Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995;22:513-521.
26. Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic size in infants and children: sonographic measurements. Am J Roentgenol 1991;157:119-121.
27. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variation of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
28. Emery AEH. Hardy-Weinberg equilibrium and the estimation of gene frequencies. In: Methodology in medical genetics: an introduction to statistical methods. 2nd ed. Philadelphia, PA: Churchill Livingstone; 1986. p. 3-11.
29. Coto E, Rodrigo L, Alvarez R, Fuentes D, Rodriguez M, Menendez LG, Ciriza C, Gonzalez P, Alvarez V. Variation at the angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis. J Cardiovasc Pharmacol 2001;38:833-839.
30. 1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998;28:803-811.
31. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999;96:2345-2349.
32. 1 in the development of pancreatic fibrosis in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Gastrointest Liver Physiol 2002;282:G549-G558.
33. Ibarra FR, Afione C, Garzon D, Barontini M, Santos JC, Arrizurieta E. Portal pressure, renal function and hormone profile after acute and chronic captopril treatment in cirrhosis. Eur J Clin Pharmacol 1992;43:477-482.
34. Lee JK, Hsieh JF, Tsai SC, Ho YJ, Kao CH. Effects of single dose of 50mg captopril in patients with liver disease and ascites. Hepatogastroenterology 2000;47:767-770.
35. Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Papp M, Flynn K, Filippatos G, Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 1998;275:L1013-L1017.
36. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, Brizio-Molteni L, Veno P. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor locker. Int J Radiat Biol 2000;76:523-532.
37. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-437.
38. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2000;97:8822-8828.
39. Action JD, Wilmott RW. Phenotype of CF and the effects of possible modifier genes. Paediatr Respir Rev 2001;2:332-339.